Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There's a reason for the resurrection. Connect the dots
GTSM @ 0016
Back from the grave. $CIVX Grey to Pink!
$CIVX to be used for bigger better things after CV blows off
Loading these cheapies
Good deduction get em while they are cheap
BYE BYE TEENS
Patience...
GTSM @ 0.0025
CSTI @ 0.0017
Keep slappin that Ask!
L2 shows next stop is 0015!!!!!
BRRREEAKKKOUTTTTT!!!!!! on thin air!!!!!
0025 or higher by the EOD!!!!
Let's make some $ today!!! $HALB!!!!
A trifecta
Bye Bye Double Zeros
"Joint Venture to Be Announced, in Detail, This Week"
CLOSED Borders, Inc.
That would be great news!!!
Buying on tha dip!
FDA APPROVAL IS COMING REALLLLL QUICK!!!!
R.I.P. Covid-19!!!!!
$LGND: Captisol is the ACTIVE ingredient in Remdesivir
Remdesivir needs LGNDs Captisol!!!
Alllright!! both are waking up LGNDZ & LGNYZ!!!!!!
Nice bump back up for LGNDZ!!!!
Trying to shake the tree!!!
$DECN NEWS TODAY !!!!
NEWS!!!! 4/7/2020 Read below:
DECN Receives Pre-EUA Acknowledgement Letter And Product Serial Number From U.S. FDA For GenViro!(TM) Covid-19 Screening Kit For Professional Use
10:15 AM ET 4/7/20 | Dow Jones
COMPANY BEGINS SCALE PURCHASES OF GENVIRO!(TM) COMPONENTS, CREATING PACKAGING USING FDA EUA LABELING GUIDANCE, APPLICATION IN PROCESS FOR GENVIRO!(TM) AT-HOME SCREENING KIT
LOS ANGELES, CA / ACCESSWIRE / April 7, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the GenViro! Covid-19 Swift Kit, is an 18-year old, diabetes and now disease testing bio-technology development firm, high-level manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for its own proprietary regulated medical devices, announces today that the company has received the Pre-EUA Acknowledgement letter from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Screening Kit. This grant by the FDA is a major milestone in our GenViro!(TM) Covid-19 test kit development, now beginning its 7(th) week since we became aware that our manufacturer and R&D professionals were living and working at Ground Zero of the Korean Covid-19 epidemic.
DECN received the Pre-EUA Acknowledgement and device serial number on Saturday, April 4, 2020. Later on this same day FDA counsel had several exchanges with FDA EUA staff. In one of those exchanges, the FDA provided Guidance for our final product testing.
Keith Berman, CEO of Decision Diagnostics commented, "We filed our final application with the FDA for EUA approval on April 3, 2020, taking out all reference to our at-home use Covid-19 kit. We submitted the application late in the afternoon EDT, and incredibly we received our Pre-EUA Acknowledgement the morning of April 4, 2020, less than 24 hours later, and on the weekend. We were so stunned by the rapid acknowledgment that we waited almost two days to inquire whether the acknowledgment was what we have come to know as the "Pre-EUA." We were assured that this letter from the FDA and the device serial number assigned are exactly what we had been hoping for."
As early as Saturday April 4, it was clear that the FDA review staff was aware that our methodology was different than those slower and older methods that had received FDA EUAs, or were in review. Although the testing requested will be rigorous, it appears that testing will require 30 known Covid-19 positive samples and 30 known Covid-19 negative samples, all samples based on venous blood. The company is now looking to contract with a hospital or commercial laboratory to complete this testing.
Mr. Berman continued, "Upon receipt of these acknowledgments from the FDA, we contacted our partners in Korea, and provided specifications for all of the major components required for the GenViro!(TM) kit that are not used or a part of our GenUltimate! TBG product. Today our partners began ordering these components to begin build, assembly and bench testing for the post-prototype version of GenViro!(TM), Point of Care kit. These activities will become part of the completion of our Design Specifications file and Design History file for Genviro!(TM), and are necessary components of all FDA cleared medical devices. "
The company plans to discuss in the coming days how we intend to identify the various coronaviruses through GenViro!(TM). Reading that discussion will be a unique opportunity. The method the company intends to use will be based upon earlier products shepherded by Messrs. Berman and Musho. We expect industry people will be surprised.
Holding steady. Gonna pop over 0.01 and stay over 0.01 sometime this week if not today.
This is money
2nd day BRRREAKKKOUTTTT!!
Rip past 0.015!!!!!!!!
Morning Gapppperrrr!!!!! @ 0.14!!!!!
Morning gapper?
Fake. BS
Count me to. Got in today.
Very surprised this held at $0.01. Going higher